Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Recurrence × pomalidomide × Clear all

Phase

Status

Sponsor Class

INDUSTRY 24 OTHER 13 OTHER_GOV 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Multiple Myeloma 1 High Grade Squamous Intra-epithelial Lesion (HSIL) 1 Disease Progression 1

Interventions

Surgical Procedures, Operative 2 Dexamethasone 2 temoporfin 1 pomalidomide 1 pembrolizumab 1 nimotuzumab 1 liposomal doxorubicin 1 ledipasvir 1 ibrutinib 1 Vinorelbine 1 Tomography, X-Ray Computed 1 Thalidomide 1 Sofosbuvir 1 Rituximab 1 Ribavirin 1 Radiotherapy 1 Radiation 1 Paclitaxel 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Mitoxantrone 1 Mastectomy 1 Irinotecan 1 Immunotherapy, Adoptive 1 Hematologic Tests 1 Drug Therapy 1 Docetaxel 1 Diagnostic Imaging 1 Dermoscopy 1 Cyclophosphamide 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03601624 2018-11-14

MM-POM-2018

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Phase 2 Unknown

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡